Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study

Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study

 

Mesele Mindachew¹, Amare Deribew², Peter Memiah³, Sibhatu Biadgilign^2,&

 

¹Department of General Public Health, College of Public Health and Medical Science, Jimma University, Ethiopia, ²Department of Epidemiology, College of Public Health and Medical Science, Jimma University, Jimma, Ethiopia, ³University of Maryland School of Medicine-Institute of Human Virology, Baltimore, MD

 

 

^&Corresponding author
Sibhatu Biadgilign, Department of Epidemiology, College of Public Health and Medical Science, Jimma University, Jimma, Ethiopia

 

 

 

 

The estimates of the global burden of disease caused by TB in 2009 are 9.4 million incident cases, 0.38 million deaths among HIV-positive people. An estimated 11-13% of incident cases were HIV-positive [1]. Most of the estimated number of cases in 2009 occurred in Africa (30%). The 22 High burden countries (HBCs) that have received particular attention at the global level since 2000 account for 81% of all estimated cases worldwide. Ethiopian ranks seventh in the list. In 2009, 26% of TB patients knew their HIV status (up from 22% in 2008), including 53% of patients in the African Region [1]. Tuberculosis (TB) has reemerged as a major threat to global public health. Its incidence is rising, particularly in countries with a high HIV prevalence [2]. HIV-infected persons have an increased risk for reactivated latent TB infection [3].

Tuberculosis (TB) is the most frequent life-threatening opportunistic disease among people living with HIV and remains a leading cause of mortality, even among persons receiving ART [4]. In 1998, the WHO and the United Nations Joint Program on HIV/AIDS (UNAIDS) issued a new IPT policy with 6 key steps as a part of the package of care for people living with HIV [5]. To prevent TB, almost 80 000 people living with HIV were provided with isoniazid preventive therapy. This is an increase from previous years, but still represents less than 1% of the estimated number of people living with HIV worldwide [1]. Isoniazid preventive therapy (IPT) reduces the risk of active TB by approximately 33% overall [6]. IPT is a key public health intervention for the prevention of TB among people living with HIV and has been recommended since 1998 by WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) as part of a comprehensive HIV and AIDS care strategy [7]. However, its implementation has been very slow and has been impeded by several barriers including lack of an accepted approach to exclude active TB disease and restricted access to isoniazid for fear of developing drug resistance. By the end of 2009, globally only 85 000 people living with HIV received IPT[1].

Despite WHO guidelines recommending IPT as part of routine HIV care, there has been little IPT implementation at country level [8]. However, in resource-limited settings these benefits are rarely realized. Obstacles include cost, interrupted drug supplies and suboptimal adherence [9, 10].The greatest obstacle to successful LTBI treatment programs is poor patient adherence[11]. To enable all those infected by HIV to benefit from these life-saving interventions, it is imperative that barriers to adherence to IPT be urgently and innovatively addressed. The objective of this study was to asses an in-depth investigation of the perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings.

 

 

Study setting

The study was conducted in Yekatit 12, Zewditu, Gandi and Minilik Hospitals, of Addis Ababa city from February 1- March 30, 2010. At present approximately 1800 adults are receiving IPT in Ethiopia. Among the study hospitals, Minilik is a central generalized referral hospital and are under Federal Ministry of Health. Yekatit 12 and Zewditu Hospitals are under Addis Ababa Regional Health Bureau, known to provide service to serve most of the patients on IPT follow up. Administratively, each of the hospitals is divided into sub city to serve clients from each sub city. Zewditu hospital gives service for Kirkose and Akaki sub cities. Yekatite 12 gives service for Yeka and Addis ketema sub cities. In the study period, according to the report obtained from the registration record of the ART unit in the respective hospitals, 1303 adults were found in the study site that were on IPT and on follow-up .

Design and participants

For this qualitative study, those interviewed were health care workers who were working on counseling of patients on the importance of drug adherence and how to recognize common adverse drug reactions associated with INH and individuals involved in, or supporting the provision of treatment and care for HIV infected clients. Purposive sampling technique was carried out to select the participants based on exposure to their patients in all circumstances, their proximity to appreciate the problems of adherence and capability to suggest interventions mechanisms for improving adherence to IPT and adherence status of their patient particularly adherence counselor, ART nurses and ART coordinators was enrolled for in-depth interview and their number were determined by saturation of ideas generated by the participants in successive interviews until their ideas become repetitive and redundant so that no new information can be gathered by further data collection .In addition, these participants were expected to present for follow up during the data collection period. In depth interview was undertaken with the health care workers with diverse social economic and demographic characteristics. Participants were eligible for the study if they expressed willingness to share their views on patient?s adherence to Isoniazid (INH).

Data collection

In-depth interviews were conducted with health workers including counselors and coordinators by the principal investigator (PI). An interviewer guide was used for the in-depth interview. In undertaking the interview sessions, a guide containing the following areas was used: Knowledge on the disease and its Treatment, Factors that influence patient adherence to IPT, Personal perspectives to the medication and Barriers and/or facilitators of patient adherence to treatment. Interviews were conducted in a hospital set up that was convenient for key informants. Field notes were written at the conclusion of each interview and all tapes were transcribed. The data collection method was checklist guided in-depth interviewing technique with health care provider who has close contact with the patient under follow up in ART clinic. After the subjects were asked for their voluntary participation, the conversation was tape recorded and further scrutinized to discover recurrent patterns and saturation of ideas before the themes was identified and interpreted. Ethical clearance was obtained from Jimma University and Addis Ababa Health Bureau.

Data analysis

The data processing and analysis procedures were begun on the first day after interview. On a daily basis, data were processed, and patterns were identified based on saturation of ideas throughout the study. The data were fully transcribed and analyzed manually. We analyzed the interview data using a thematic content analysis approach. This approach is a comparative process by which the various accounts gathered are compared with each other to classify those "themes" that recur or are common in the data set [12]. All transcripts were read several times by the investigators separately to bring out the main ideas. Later the data was reviewed and combined into broader categories in terms of key variables; it was then ordered, reduced and classified or coded (sorted out), displayed, summarized and finally interpreted.

 

 

The purpose of qualitative research was to obtain in-depth responses concerning what people think and feel concerning a particular area of interest. To this end, the research team employed an in-depth interview with health care providers; namely ART nurse, adherence counselors and ART coordinators. A total of 12 key informants were purposively selected and volunteered to participate. A total of 12 patients, 7(58%) females were interviewed. Ages ranged from 27 to 48 years, with a mean age of 34 years. Proportional allocation was made according to their profession (Table 1).

Three major themes influencing IPT uptake and adherence identified includes: - A) factors related with patient provider interaction, B) patient related factors, C) socio-environmental factors, barriers and IPT drugs.

Factors related with patient provider interaction

The first question asked under this theme was to describe patient-provider relation in relation to barriers for patient?s adherence to IPT. Except four participants the rest indicated that they had good relation with the patient, most of the participant said that the patients had good experience to attend regular and follow up appointments, they accept and practice as advised, they ask questions when faced with confusion related with the regimen, they ask for help when they develop side effects, but in contrast to this a 31 years old female adherence counselor said

In this regard 48 years old ART coordinator also emphasized on the provision of necessary information to the client, he said,

In relation to this one female ART nurse also emphasized

Similarly a 29 male ART nurse from other hospital said also,

Patient related factors

Under this theme majority of the respondents relate this group of factors as a barrier and facilitator of adherence. When they were asked to evaluate the knowledge of patients about the disease and treatment, most of them raised similar issues. As they reported, though the client didn?t have deep knowledge concerning the regimen and the importance of adherence, in all hospitals the client had good level of adherence In line with this a 45 years old Medical doctor who functions as the ART clinic coordinator said,

In contrast to the above idea a 38 years old male adherence counselor from other hospital said:

The other most frequently mentioned barriers of adherence to IPT as most of the respondent indicated the patient have mental health issues which make reluctant to attend follow-up and clinical appointment regularly, to stick to the scheduled time of drug administration(mental health issues directly or indirectly related to the disease) and which might also affect their understanding of the regimen, the disease and their understanding of all the instructions and information given by health care provider.

In line with this, a 40 years old adherence counselor from one of the hospitals said:

As raised by most of the key informant, the other important factor which had great emphasis was that the patients are not willing to disclose their sero-status to their family members or to others who are close to them and as indicated by the key informants. Most of the patients did that because they claimed fear of disturbing or losing the normal relationships they had with their families and within their communities as major reasons for not disclosing their sero-status (fear of stigma and discrimination) and due to this they lack the courage to take the drugs in public forcing them to miss some of their prescribed medication.

Socio-environmental factors

When they were asked about the requirements/recommendation to enhance adherence status of the patient, the efficacy of the therapy, all participants suggested that social support from a family, community, NGOs and others were important factor in assisting them to adhere to their drug regimen; and also it is expected that the government should provide more emphasis to this new program , all heath care providers should be well trained and take responsibilities to give care, support and information concerning the drug and the disease to the patient so that to promote and maintain maximum adherence.

 

 

In developing countries, preventive therapy has not received much emphasis[13]. However, with the advent of HIV infection, TB has emerged as a major opportunistic infection, particularly in developing countries.HIV infection is the single greatest risk factor for the reactivation of latent mycobacterial infection[14]. In the 2009 WHO TB Control Report, the WHO estimates that fewer than 0.5% of HIV-infected persons Worldwide have received IPT[15]. In our study, most of the respondents, the heath care workers, demonstrated that they didn?t have the capacity to provide adequate information and prescription to the patients as they didn?t get the training. The finding is similar to other studies. The lack of familiarity and confidence in IPT prescribing was evidenced not only by variable and inconsistent prescribing practices, but by healthcare workers? own admission that they were unclear about its benefits. In a programme that has promoted IPT since its inception in 1999, this is even more remarkable, and policy clarification and dissemination of accurate information is required [16]. Prior to implementation of THRio, physician knowledge about the national recommendations for TB prevention in HIV patients was limited [17]. In other studies clinicians are also concerned about toxicity of isoniazid and maintaining adherence to the IPT regimen [18]. In Tanzania, the reasons provided by the completers for IPT/ decision to complete IPT were fear of TB, understanding of the importance of IPT, and fear of TB and HIV complications [19]. Likewise, Compared to non-completers, completers were more likely to be highly motivated to adhere [11]. So the Application of intensive patient education, enablers may improve adherence [20, 21]. The Constraints mentioned for barrier for implementation were, among others: limited motivation and knowledge by counselors to discuss TB issues during HIV pre- and post test Counseling [22]. Among physicians who did not provide IPT, the most common reason were patient?s poor adherence (24.8%), IPT might induce the occurrence of Isoniazid-resistant TB cases (20.2%), concern about side effect of Isoniazid (12.8%), and they felt that IPT was not beneficial (6.2%)[23]. The high rate of completion was due to a number of factors, including personal experience with TB, knowledge gained from counseling, family approval and proximity to the clinic [19]. One of the factors that the health care provider revealed about their patients is that they forget to take their pill and keep appointments. Similarly in there, are reported reasons for poor adherence including lack of transport, being away from home, loss of drugs and forgetfulness [24] and patients who report they sometimes forget to take their medication were more likely to have a negative urine test [25]. This was also previously reported as a predictor in another study of patients on INH for LTBI [26]. In a similar fashion there was inadequate patient-provider relationship as was evidenced from our study due to high patient volumes. A study in Brazil showed that although physicians at the public health units say they are too busy, tense and solitary, they evaluated their health units very positively [17].

One of the factors that identified for barriers for the implementation was HIV sero status?s disclosure. Other study finding supports this finding. Five of the six patients in the group who completed TBPT had disclosed to someone who was able to support them emotionally and financially. However, the fear of rejection and stigmatization prevented people from disclosing their HIV status [27]. A preventive therapy service requires supervision of clients for adherence to therapy. Convincing patients who are essentially well to take medication for an extended period is difficult. This requires patient education which is time consuming and may not lead to sustained adherence[13]. In rural South Africa study, Barriers to adherence included fear of stigmatization, the belief that HIV is incurable, and a reluctance to take medication in the absence of symptoms but disclosure of HIV status, social and family support, and a supportive clinic environment positively influenced adherence[27]. In the same study important barriers to adherence noted among all groups interviewed include fear of stigmatization in relation to their HIV status, lack of money for food and transport, the belief that HIV is incurable by Western medicine[27].

Along with this, fear of stigma and discrimination incur a lot for disclosure of the status and for this reason they lack courage to take their pills in public. Similar studies demonstrated and support our finding. Those believing they have a higher above average chance of getting active TB without INH were more likely non-adherent. Patients may perceive stigma or conceal their condition and its treatment, which could interfere with adherence. Alternatively, knowledge of the danger of TB may motivate them to share or sell their INH to others who are also at risk[25]. In South Africa five of the six patients in the group who completed TBPT had disclosed to someone who was able to support them emotionally and financially. However, the fear of rejection and stigmatization prevented people from disclosing their HIV status and Lack of social and family support was identified as adversely affecting adherence. Similarly the presence of supportive nurses in the clinic also appears to play a role in the decision to regularly visit the clinic and pick up medication [27]. At an ART pilot initiative in South Africa, good adherence was attributed to even more rigorous enrolment criteria, including, the requirement to attend support groups, openness about HIV status, and proven adherence to other chronic disease medications[28]. This is similar to qualitative research done in Thailand where those who completed TBPT cited the acceptance of their HIV status, their concern for their families? well-being, and good relationships with health care providers as promoting good adherence[29].

 

 

The study demonstrated that uptake of the implementation of IPT is facing a challenge in resource limited settings. As much as the patients are to play a part in ensuring adherence to their treatment plan, providers must become a part of the solution. By identifying barriers to adherence, steps to improve adherence rates can be put into place. These include collaboration, open communication between healthcare professionals and patients regarding medication regimens, as well as education provided to patients about the benefits of disclosure, medication adherence and adherence to clinic appointments. This study also highlights the recalled provision of capacity building and awareness creation mechanism by health officials ensuring proper integration of the health system to support good adherence patterns for patients on IPT.

 

 

All authors declare that they have no conflict of interest associated with the publication of this manuscript.

 

 

MM conceived and designed the study and collected data in the field, performed analysis, interpretation of data, and draft the manuscript. AD assisted with the design, interpretation of data and the critical review of the manuscript. SB participated in design and helped to draft the manuscript and critically reviewed the manuscript. PM assisted with interpretation of data ,drafting the manuscript and the critical review of the manuscript. All authors approved and read the final manuscript. All authors participated in critical appraisal and revision of the manuscript.

 

 

This study was funded by Jimma University. We thank all participants for devoting their time to take part in this study.

 

 

Table 1: Socio-demographic attributes of the respondents participated in Addis Ababa hospitals, 2010

 

 

1. WHO. Global tuberculosis control: a short update to the 2010 Report. 2010. Geneva, Switzerland. World Health Organization. Google Scholar


2. Corbett EL WC, Walker N, Maher D, Williams BG, Raviglione MC. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003; 163(9):1009-1021. PubMed | Google Scholar


3. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989; 320(9):545-550. PubMed | Google Scholar


4. Anand D MV, Reuben G, Mazuwa B, Mayada Y, & Charlie Gilks. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ. 2010; 88(4):253-259. PubMed | Google Scholar


5. UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV. report of a meeting held in Geneva. 18-20 February 1998. Geneva. UNAIDS. Google Scholar


6. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171. PubMed | Google Scholar


7. World Health Organization. Policy statement on preventive therapy against tuberculosis in people living with HIV. 1999. Geneva. World Health Organization. Google Scholar


8. Churchyard GJ SF, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis. 2007; 196 (Suppl 1):S52-62. PubMed | Google Scholar


9. Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, McCarthy AE. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis. 2006 Jun 13;6:97. PubMed | Google Scholar


10. Zachariah R HA, Luo C, Bachman G, Graham SM. Scaling up co-trimoxazole prophylaxis in HIV-exposed and HIVinfected children in high HIV-prevalence countries. Lancet Infect Dis. 2007; 7(10):686-693. PubMed | Google Scholar


11. Nyamathi AM CA, Nahid P, Gregerson P, Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis. 2006; Jul 7(10):775-782. PubMed | Google Scholar


12. Green J & Thorogood N. Qualitative Methods for Health Research-1st edition. 2004. London. Sage publications. PubMed | Google Scholar


13. Hawken MP, Muhindi DW. Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries. Int J Tuberc Lung Dis. 1999; 3(8):646-650. PubMed | Google Scholar


14. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tubercle Lung Dis. 1992; 73(6):311-321. PubMed | Google Scholar


15. WHO. Global tuberculosis control: a short update to the 2009 report. 2010. Geneva. World Health Organization. PubMed | Google Scholar


16. Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, Grant AD. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS. 2010; 24( Suppl 5):S45-48. PubMed | Google Scholar


17. Durovni B CS, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010; 24 ( Suppl 5):S49-56. PubMed | Google Scholar


18. Eldred LJ CG, Durovni B, Godfrey-Faussett P, Grant AD, Getahun H, Chaisson RE. Isoniazid preventive therapy for HIV-infected people: evidence to support implementation. AIDS. 2010; 24( Suppl 5):S1-3. PubMed | Google Scholar


19. Munseri PJ TE, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008; 12(9):1037-1041. PubMed | Google Scholar


20. Morisky DE, Malotte CK, Choi P, Davidson P, Rigler S, Sugland B, Langer M. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q. 1990; 17(3): 253-267. PubMed | Google Scholar


21. Cuneo WD, Snider DE Jr. Enhancing patient compliance with tuberculosis therapy Clinics. Chest Med. 1989; 10(3): 375-380. PubMed | Google Scholar


22. Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS. 1995; 9(3):267-273. PubMed | Google Scholar


23. Hiransuthikul N, Hiransuthikul P, Nelson KE, Jirawisit M, Paewplot R, Kasak S. Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand. Southeast Asian J Trop Med Public Health. 2005; 36(5):1208-1215. PubMed | Google Scholar


24. Lugada ES, Watera C, Nakiyingi J, Elliott A, Brink A, Nanyunja M, French N, Antivelink L, Gilks C, Whitworth J. Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda. Int J Tuberc Lung Dis. 2002; 6(4):326-331. PubMed | Google Scholar


25. Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, McCarthy AE. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis. 2006; 13(6):97. PubMed | Google Scholar


26. Pekovic V, Mayanja H, Vjecha M, Johnson J, Okwera A, Nsubuga P, Mugerwa R, Ellner J, Whalen C. Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. J Clin Epidemiol. 1998; 51(7):597-607. PubMed | Google Scholar


27. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM. Adherence to TB preventive therapy for HIV-positive patients in rural South Africa: implications for antiretroviral delivery in resource-poor settings. Int J Tuberc Lung Dis. 2005; 9(3):263-269. PubMed | Google Scholar


28. Médecins San Frontières. Providing antiretroviral therapy at primary health care clinics in resource poor settings: Preliminary Report, 2001-May 2002. 2006. Cape Town, South Africa. Médecins San Frontières and School of Public Health and Primary Health Care, University of Cape Town. PubMed | Google Scholar


29. Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. AIDS. 1997; 11(1):107-112. PubMed | Google Scholar